Drugs for Rheumatoid Arthritis Flashcards
anakinra
IL-1 receptor blocker
how are adalimumab and etanercept different in mech?
- etanercept binds only soluble TNF-alpha
- adalimumab binds both soluble and transmembrane
methotrexate
-DHFR inhibitor, inhibits folate dependent steps in purine synthesis to inhibit DNA synthesis
etanercept
- mech
- therapeutic use
- adverse effects (3)
‘intercept TNF alpha’
- binds to soluble TNF-alpha
- used for RA
- side effects:
1. injection site reactions
2. increased risk of infections
3. lymphoma in children
tofacitinib
- mech
- use
- side effects –2
- JAK inhibitor
- used in active RA pts who had inadequate repsonse from methotrexate
adverse effects:
- increase infection risk
- increase in cholesterol
Infliximab
TNF alpha inhibitor
tocilizumab
- mech
- therapeutic use
- side effects (2)
- IL-6 receptor blocker. (both soluble and transmembrane)
- used for adult RA with poor response to TNF anatgonists
side effects:
- injection site reactions
- increase infection risk
adalimumab
- mech
- therapeutic use
- adverse effects–3
- IgG that binds TNF-alpha (both soluble and transmembrane)
- active RA, juvenile idiopathic arthritis
- side effects:
1. injection site reactions
2. increased risk of infections
3. lymphoma in children
azathioprine
- prodrug to 6-MP
- purine antimetabolite to inhibit DNA synthesis
DMARDs
disease-modifying anti-rheumatic drugs
-protein drugs that target cytokines and cell surface molecules
abatacept
- inhibits T-cell activation by blocking the CD28/B7 costimulation of APCs on T cells.
- abatecept (which has CTLA-4) competes with B7 to bind CD28. This induces anergy.
hydroxychloroquine
- mech not understood
- useful as oral tx for early RA
- long term toxicity: irreversible retinal damage
leflunomide
-inhibits dihydroorotate DH (DHODH), an enzyme that produces UMP
what drugs require the pt to be screened for latent TB infection and monitored while taking it? why?
- etanercept, adalimumab, infliximab
- as TNF-alpha inhibitor, the inflammatory response is reduced. This could allow a latent TB infection to relapse
rituximab
-Ab against CD20 antigen of B-cells, inducing complement and destroying them